Products in Trouble

Arcoxia: In March, Merck withdrew its application to sell Arcoxia (etoricoxib), a treatment for arthritis, chronic and acute pain, and dysmenorrhea, stating it was to "better position the product to compete successfully." Although Merck remains in the arthritis market with Vioxx (rofecoxib), the removal of Arcoxia is likely to benefit Pharmacia and Pfizer, who co-market hot-selling Celebrex (celecoxib), which had $3.11 billion in sales last year.

For full article Click Here